首页> 外文期刊>中国癌症研究(英文版) >Potential effects of CRM1 inhibition in mantle cell lymphoma
【24h】

Potential effects of CRM1 inhibition in mantle cell lymphoma

机译:抑制CRM1在套细胞淋巴瘤中的潜在作用

获取原文
获取原文并翻译 | 示例
       

摘要

Mantle cell lymphoma (MCL) is an aggressive histotype of B-cell non-Hodgkin lymphoma.The disease has no known cure,which prompts the urgent need for novel therapeutic agents.Chromosomal region maintenance 1 (CRM1) may play a role in human neoplasia and serve as a novel target of cancer treatment.This study summarizes MCL pathogenesis and determines the involvement of CRM1 in the regulation of several vital signaling pathways contributing to MCL pathogenesis,including the pathways of cell cycle progression,DNA damage response,phosphoinositide kinase-3,nuclear factor-κB activation,and chromosomal stability.A preclinical study is also presented to compare the CRM1 status in MCL cell lines and primary MCL cells with normal B cells,as well as the therapeutic efficiency of CRM1 inhibition in MCL in vitro and in vivo,which make these agents potential targets of novel MCL treatments.
机译:幔细胞淋巴瘤(MCL)是B细胞非霍奇金淋巴瘤的一种侵袭性组织型。该病尚无治愈方法,这迫切需要新型治疗剂。染色体区域维持1(CRM1)可能在人类肿瘤形成中起作用这项研究总结了MCL的发病机理,并确定了CRM1参与调节几个重要的MCL发病机理的重要信号通路,包括细胞周期进程,DNA损伤反应,磷酸肌醇激酶-3等。 ,核因子κB活化和染色体稳定性。还进行了临床前研究,比较了MCL细胞系和原代MCL细胞与正常B细胞​​中CRM1的状态,以及CRM1抑制在体外和体外对MCL的治疗效率。体内,使这些药物成为新型MCL治疗的潜在靶标。

著录项

  • 来源
    《中国癌症研究(英文版)》 |2012年第4期|374-387|共14页
  • 作者

    Ke-Jie Zhang; Michael Wang;

  • 作者单位

    Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen 361004, China;

    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston 77030, USA;

    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston 77030, USA;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号